MBX Biosciences

MBX Biosciences At MBX Biosciences, our mission is to help transform the lives of people living with obesity and rare endocrine disorders.

Using our peptide delivery platform, we are advancing a pipeline of novel Precision Endocrine Peptides (PEPs)™ designed to overcome key limitations of existing treatments and improve efficacy, tolerability, safety, and convenience. Our lead candidate, canvuparatide (MBX 2109) – a potential once-weekly parathyroid hormone (PTH) replacement therapy for the treatment of chronic hypoparathyroidism – i

s preparing for Phase 3 development. We are also advancing an obesity portfolio including MBX 4291, a GLP-1/GIP co-agonist prodrug in Phase 1 development, and MBX 5765, an amycretin prodrug in preclinical development. In addition, we are on track to nominate its GLP-1/GIP/GCG receptor prodrug candidate in Q3 2026, further expanding its obesity pipeline to potentially address the full spectrum of patient needs. Learn more about our pipeline and peptide delivery platform: www.mbxbio.com.

Address

Carmel, IN

Website

Alerts

Be the first to know and let us send you an email when MBX Biosciences posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to MBX Biosciences:

Shortcuts

Share

Category